Source: sciencedirect.com/science/a... (free access)
Abstract
The human gut, which contains a diverse microbiome, plays an important role in maintaining physiological balance and preserving the immune system. The complex interplay between the central nervous system (CNS) and the gut microbiome has gained significant attention due to its profound implications for overall health, particularly for gut and brain disorders. There is emerging evidence that the gut-brain axis (GBA) represents a bidirectional communication system between the CNS and the gastrointestinal tract and plays a pivotal role in regulating many aspects of human health. Ginseng has shown potential to ameliorate conditions associated with dysbiosis, such as gut and CNS disorders by restoring microbial balance and enhancing gut barrier function. This comprehensive review provides valuable insights into the potential of ginseng as a herbal modulator of GBA as a therapeutic intervention for preventing and treating gut and neurological diseases via microbiota regulation to ultimately enhance overall health. Furthermore, we emphasize the therapeutic benefits of ginseng, its ability to enhance beneficial probiotics, such as Firmicutes, Bacteroides, Lactobacillus, Bifidobacterium, and Akkermansia while reducing pathogenic bacteria prevalence, such as Helicobacter, Clostridium, and Proteobacteria. Although the connection between ginseng regulation of microbial communities in response to the gut and neuropsychiatric disorders is lacking, additional investigations are warranted to elucidate the underlying mechanisms, optimize dosages, and explore the clinical relevance of ginseng in promoting GBA balance and ultimately overall health.
KRG = Korean Red Ginseng
Part from the article:
"Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder involving gut-brain interactions, characterized by altered bowel habits and chronic recurrent abdominal pain, and occurs in up to 4.8 % of the global population [8,57].
IBS patients (>50 %) have comorbid depression or anxiety [58]. IBS patients have higher levels of anxiety and depression compared to controls; Between 30 % and 40 % of IBS patients have a comorbid anxiety or depression disorder [59]. Notably, the diagnosis of IBS precedes mood disorders, which means that in some patients, primary intestinal dysfunction may contribute to mood disorders [58,60]. Furthermore, individuals with higher baseline levels of anxiety and depression were significantly more likely to develop IBS [58,60]. Dysregulation of the gut microbiome due to depression can manifest as gastrointestinal symptoms, with IBS being the most common, but often accompanied by an increase in Bacteroides and Firmicutes [35] as shown in Fig. 1. When the gut microbiota of IBS mice was compared to that of control mice at the genus level, increased levels of Prevotella species but decreased levels of Bacteroides and Parabacteroides were observed [61]. In another study, KRG significantly reduced the anxiety-like behavior, frequency of visceral pain, and macroscopic score in IBS mice [8]. Stool consistency improved and bowel frequency increased in older women treated with FRG [43]. Moreover, KRG remarkably increased the beneficial gut microbes comprising Lactobacillus (L.) reuteri, Lactobacillus johnsonii, and Parabacteroides goldsteinii in IBS mice [8]. L. reuteri reportedly reduces inflammatory cytokine levels and strengthens the intestinal barrier [62]. L. johnsonii consumption also stimulates mucin secretion, which improves the intestinal barrier [63]. In mice injected with zymosan to induce symptoms similar to human IBS, 100 mg/kg of red ginseng (RG) increased levels of the beneficial bacteria L. johnsonii, L. reuteri and P. goldsteinii levels were all increased. However, the levels of P. goldsteinii, unlike L. johnsonii and L. reuteri, recovered to normal control levels, suggesting that normalization of healthy gut function is associated with the presence of P. goldsteinii [8]. RG significantly inhibited the expression of IL-1β in the gut and c-fos in the prefrontal cortex [8]. Moreover, treatment with RG mitigated abdominal pain-related behaviors, potentially due to a reduction in visceral hypersensitivity. Visceral pain in IBS has been linked to activation of IL-1β and TNF-α in the intestinal wall [64], suggesting that gastrointestinal symptoms are integral to conditions involving gut-brain interactions, such as IBS, which often co-occur with psychiatric diagnoses and psychological symptoms [8,65]. These findings are further supported by the evidence of high correlations between patients with IBS and those with depression and anxiety, and comorbidities found among these patients [65]."